Chimeric Autoantigen Receptor (CAAR) T Cell Therapy for Graves' Disease ID: 2023-020

An innovative treatment for Graves' disease using engineered T cells to target and eliminate disease-causing B cells.

Technology Overview

This technology involves the development of chimeric autoantigen receptor (CAAR) T cell therapy, specifically designed to combat Graves' disease by targeting and destroying autoreactive B cells. By utilizing molecular modeling to identify specific epitopes on the thyroid-stimulating hormone receptor (TSHR), this approach allows for the precise targeting of problematic B cells, offering a potential cure by addressing the root cause of the disease.

Key Advantages

• Targets the root cause of Graves' disease, offering a potential cure rather than symptom management
• Provides a long-term solution by integrating into the patient's immune system to prevent relapse
• Capable of precise targeting, minimizing the risk of off-target effects and collateral damage
• Applicable to other autoimmune diseases, showcasing its versatility and broad therapeutic potential

Problems Addressed

• Overcomes the limitations of traditional treatments that fail to address the underlying cause of Graves' disease
• Reduces the risk of hypothyroidism and disease relapse associated with current treatment options
• Addresses the need for targeted therapies in autoimmune diseases with minimal side effects

Market Applications

• Treatment for Graves' disease and potentially other autoimmune disorders
• Development of personalized medicine approaches for immune system-related diseases
• Research tool for studying the interaction between engineered T cells and autoreactive B cells

Additional Information

Technology ID: 2023-020
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025